Bluebird Bio (BLUE) said Friday it agreed to be acquired by Carlyle Group (CG) managed funds and SK Capital Partners.
Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027.
Shares slumped 41% following a surge in intraday trading volume to over 4.5 million from a daily average of about 392,000.
AXT (AXTI) reported a wider Q4 non-GAAP loss late Thursday compared with a year ago and sequentially. Wedbush adjusted AXT's price target to $4.50 from $5.50 while maintaining its outperform rating.
Shares of AXT sank 31%, with intraday trading volume catapulting to over 5.3 million versus a daily average of about 361,000.
Akamai Technologies (AKAM) has "limited" short-term growth opportunities, BofA Securities said in a note Friday, following the company's Q4 results overnight. BofA downgraded Akamai to neutral from buy and cut its price target to $100 from $125.
Shares fell 20%, with intraday trading volume surging to over 13.6 million versus a daily average of about 1.7 million.
Price: 4.15, Change: -2.90, Percent Change: -41.12
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。